LARIMAR THERAPEUTICS INC

LRMRNASDAQ

🏆 #2689 by market capEarnings Nov 5US Equity

$4.31▼ $0.01 (−0.12%)

Live

1h▼ 0.2%

24h▼ 0.1%

7d▲ 5.1%

14d▲ 19.1%

30d▲ 15.7%

1y▲ 16.5%

🏦Market Cap

$448M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $4.28 – $4.39
52-Week Range: $2.72 – $6.42
Volume: $4.18B
Avg Volume: $3.58B
Shares Outstanding: 103.9M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $64M
Last Q Revenue: $18M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.99
Dividend Yield: —

Why Investors Own LRMR

✓High-growth profile — revenue up +6.9% YoY with expanding US Equity exposure.
✓Healthy economics — 77% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$64M▲ +2.9% YoY

Gross Margin (TTM)

76.6%▲ +0.4% YoY

Operating Income (TTM)

$12M▲ +2.9% YoY

Free Cash Flow (TTM)

$15M▲ +2.9% YoY

About LARIMAR THERAPEUTICS INC

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

🦦